DoH Policies screened during the period: 1 October 2023 – 31 December 2023
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA912 - Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (PDF 510KB)
- NICE Technology Appraisal TA913 - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (PDF 513KB)
- NICE Technology Appraisal TA915 - Pegunigalsidase alfa for treating Fabry disease (PDF 512KB)
- NICE Technology Appraisal TA916 - Bimekizumab for treating active psoriatic arthritis (PDF 515KB)
- NICE Technology Appraisal TA918 - Bimekizumab for treating axial spondyloarthritis (PDF 515KB)
- NICE Technology Appraisal TA919 - Rimegepant for treating migraine (PDF 514KB)
- NICE Technology Appraisal TA930 - Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (PDF 514KB)
- NICE Technology Appraisal TA924 - Tirzepatide for treating type 2 diabetes (PDF 558KB)
- NICE Technology Appraisal TA922 - Daridorexant for treating long-term insomnia (PDF 510KB)
- NICE Technology Appraisal TA920 - Tofacitinib for treating active ankylosing spondylitis (PDF 513KB)
- NICE Technology Appraisal TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (PDF 514KB)
- NICE Technology Appraisal TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (PDF 513KB)
- NICE Technology Appraisal TA921 - Ruxolitinib for treating polycythaemia vera (review of TA356) PDF 511KB)
- NICE Technology Appraisal TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis (PDF 513KB)
- NICE Technology Appraisal TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (PDF 623KB)
- NICE Technology Appraisal TA926 - Baricitinib for treating severe alopecia areata (PDF 511KB)
- NICE Technology Appraisal TA929 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (PDF 515KB)
- NICE Technology Appraisal TA934 - Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms (PDF 514KB)
- NICE Technology Appraisal TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa (PDF 512KB)
- NICE Technology Appraisal TA928 - Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (PDF 513KB)
- NICE Technology Appraisal TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia (PDF 558KB)
- NICE Technology Appraisal TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (rapid review of TA885) (PDF 513KB)
- The Provision of Health Services to Persons Not Ordinarily Resident (Amendment) Regulations (Northern Ireland) 2023 (PDF 520KB)
- Infected Blood Inquiry - Enhanced financial support for Hepatitis C stage 1 (PDF 537KB)
- ‘Healthy Futures’ obesity strategic framework - EQIA and RNIA (PDF 386KB)